Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
Table 5
Clinical trials for VEGF trap in ovarian cancer.
Trial
Phase
Stage of the disease
Results
Single agent
NCT00327171 (ARD6122, AVE0005)—Completed
II
Platinum-resistant and topotecan and/or liposomal doxorubicin-resistant advanced ovarian cancer
Preliminary results from 162 randomized patients showed a partial response of 11%. [53]
NCT00396591 (ARD6772)—Completed
II
Platinum-resistant and topotecan and/or liposomal doxorubicin-resistant advanced ovarian cancer with recurrent symptomatic malignant ascites
First results demonstrated the efficacy of two weekly IV aflibercept in prolonging the time to repeat paracentesis in eight out of ten evaluable patients. [54]
NCT00327444 (EFC6125)—Completed
II/III
Platinum-resistant and topotecan and/or liposomal doxorubicin-resistant advanced ovarian cancer with recurrent symptomatic malignant ascites
Results are awaited
Combination with chemotherapy (docetaxel)
NCT00436501 (MDA-2006-0329)—ongoing
I/II
Recurrent or persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer
Ongoing
IV: Intravenous, VEGF: Vascular endothelial growth factor.
*Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.